Aline Fusco Fares
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aline Fusco Fares has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Geoffrey Liu
Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada
4 shared publications - Wei Xu
Department of Biostatistics, Princess Margaret Cancer Centre and Dalla Lana School of Public Health, Toronto, Canada
3 shared publications - Adonina Tardón
14Health Research Institute of Asturias (ISPA) and Faculty of Medicine, University Nebrija, Campus Berzosa, Madrid, Spain
2 shared publications - Ana Caroline Zimmer Gelatti
PUC-RS, Porto Alegre, Brazil
2 shared publications - Carlos Henrique Andrade Teixeira
Hospital Alemão Oswaldo Cruz (HAOC), São Paulo, Brazil
2 shared publications - Clarissa Baldotto
Instituto D’Or de Pesquisa e Ensino - Department of Clinical Oncology , Rio de Janeiro
2 shared publications
Latest Publications
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2600042
Treatment of ALK+ Non–Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918)
PURPOSE: ALK rearrangements occur in 5.4% of Brazilian patients with non–small cell lung cancer (NSCLC). Data on treatment patterns, access to ALK inhibitors, and survival outcomes are scarce. MATERIALS AND METHODS: LACOG/GBOT 1918 is a retrospective, observational study that included patients diagnosed with ALK-positive NSCLC between January 2015 and December 2020 in 12 Brazilian public and private centers. Data were extracted from patient records, including clinic-epidemiologic features, diagnosis, ALK testing methods, treatment patterns, and outcomes. Data were analyzed using descriptive statistical methods. RESULTS: A total of 101 patients were enrolled. The median age was 55 years (range, 18-86), and 55.4% were female. Immunohistochemistry was the most frequently used method for ALK testing. The median time from the first symptom to diagnosis was 2 months, from diagnosis to ALK testing 1.7 months, and from diagnosis to treatment initiation 1.7 months. Among patients receiving first-line treatment, only 47.9% received ALK inhibitors (53.9% private v 22.2% public), with crizotinib being the most used. For second-line treatment, 66.0% of patients received ALK inhibitors, with alectinib being the most used (50%). Most treated patients had access to ALK inhibitors in some line of treatment (83.3% private v 72.2% public); however, in the public setting, targeted treatment was restricted to first-generation and second-generation ALK inhibitors. The 3-year overall survival (OS) rate was 82.6% (95% CI, 72.6 to 89.2), with a lower 3-year OS in the public setting (61.4% public v 87.2% private; P = .0279). CONCLUSION: Access to targeted ALK therapy is limited in the public health care system, reflecting poor clinical outcomes. Public health measures are necessary to minimize the differences between these two systems.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (6) , e2600042
Treatment of ALK+ Non–Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918)
PURPOSE: ALK rearrangements occur in 5.4% of Brazilian patients with non–small cell lung cancer (NSCLC). Data on treatment patterns, access to ALK inhibitors, and survival outcomes are scarce. MATERIALS AND METHODS: LACOG/GBOT 1918 is a retrospective, observational study that included patients diagnosed with ALK-positive NSCLC between January 2015 and December 2020 in 12 Brazilian public and private centers. Data were extracted from patient records, including clinic-epidemiologic features, diagnosis, ALK testing methods, treatment patterns, and outcomes. Data were analyzed using descriptive statistical methods. RESULTS: A total of 101 patients were enrolled. The median age was 55 years (range, 18-86), and 55.4% were female. Immunohistochemistry was the most frequently used method for ALK testing. The median time from the first symptom to diagnosis was 2 months, from diagnosis to ALK testing 1.7 months, and from diagnosis to treatment initiation 1.7 months. Among patients receiving first-line treatment, only 47.9% received ALK inhibitors (53.9% private v 22.2% public), with crizotinib being the most used. For second-line treatment, 66.0% of patients received ALK inhibitors, with alectinib being the most used (50%). Most treated patients had access to ALK inhibitors in some line of treatment (83.3% private v 72.2% public); however, in the public setting, targeted treatment was restricted to first-generation and second-generation ALK inhibitors. The 3-year overall survival (OS) rate was 82.6% (95% CI, 72.6 to 89.2), with a lower 3-year OS in the public setting (61.4% public v 87.2% private; P = .0279). CONCLUSION: Access to targeted ALK therapy is limited in the public health care system, reflecting poor clinical outcomes. Public health measures are necessary to minimize the differences between these two systems.
- 1 November 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2400122
Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies
PURPOSE: Mounting data suggest that lower doses of anti-PD(L)1 agents can be as efficacious as label-approved doses at a fraction of its cost. We compare the outcomes of patients treated with low-dose (LD) and with conventional-dose (CD) anti-PD(L)1 agents. METHODS: This observational study evaluates the outcomes of patients with solid malignancies treated with anti-PD(L)1 agents (LD or CD) at Hospital de Base, Brazil. Patients were classified as receiving LD if the dose administered in the first cycle was below the label-approved dose. Efficacy outcomes, including best clinical overall response rate (cORR), clinical progression-free survival (cPFS), and overall survival (OS), were evaluated. RESULTS: From January 2020 to May 2023, 71 patients were included: 49 (69%) with LD and 22 (31%) with CD agents. The most frequent tumor sites were the lung (41% LD, 22.9% CD) and skin (melanoma; 24.6% LD, 50% CD). Most of the patients were treated with pembrolizumab (65% LD and 72% CD). The mean dose of pembrolizumab was 95.3 mg (1.5 mg/kg) in LD and 168.7 mg (2.12 mg/kg) in CD groups, once a day, q21d (every 21 days). After a median follow-up of 10.9 months, there were no significant differences between LD versus CD in cORR (38.1% v 35.2%, P = .31), cPFS (5.3 m v 7 m, P = .36), and OS (12.8 m v not reached, P = .17). A subgroup analysis with patients receiving pembrolizumab was performed, and similar results were obtained. CONCLUSION: Our study found no differences in cORR, cPFS, and OS between patients treated with LD and CD anti-PD(L)1. LD anti-PD(L)1 could be an alternative to promote accessibility, which warrants further investigation in randomized trials.
- 1 November 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2400122
Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies
PURPOSE: Mounting data suggest that lower doses of anti-PD(L)1 agents can be as efficacious as label-approved doses at a fraction of its cost. We compare the outcomes of patients treated with low-dose (LD) and with conventional-dose (CD) anti-PD(L)1 agents. METHODS: This observational study evaluates the outcomes of patients with solid malignancies treated with anti-PD(L)1 agents (LD or CD) at Hospital de Base, Brazil. Patients were classified as receiving LD if the dose administered in the first cycle was below the label-approved dose. Efficacy outcomes, including best clinical overall response rate (cORR), clinical progression-free survival (cPFS), and overall survival (OS), were evaluated. RESULTS: From January 2020 to May 2023, 71 patients were included: 49 (69%) with LD and 22 (31%) with CD agents. The most frequent tumor sites were the lung (41% LD, 22.9% CD) and skin (melanoma; 24.6% LD, 50% CD). Most of the patients were treated with pembrolizumab (65% LD and 72% CD). The mean dose of pembrolizumab was 95.3 mg (1.5 mg/kg) in LD and 168.7 mg (2.12 mg/kg) in CD groups, once a day, q21d (every 21 days). After a median follow-up of 10.9 months, there were no significant differences between LD versus CD in cORR (38.1% v 35.2%, P = .31), cPFS (5.3 m v 7 m, P = .36), and OS (12.8 m v not reached, P = .17). A subgroup analysis with patients receiving pembrolizumab was performed, and similar results were obtained. CONCLUSION: Our study found no differences in cORR, cPFS, and OS between patients treated with LD and CD anti-PD(L)1. LD anti-PD(L)1 could be an alternative to promote accessibility, which warrants further investigation in randomized trials.
- Open Access
- 1 March 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 31 (3) , 679-687
Accounting for EGFR Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data
Background: Somatic EGFR mutations define a subset of non–small cell lung cancers (NSCLC) that have clinical impact on NSCLC risk and outcome. However, EGFR-mutation-status is often missing in epidemiologic datasets. We developed and tested pragmatic approaches to account for EGFR-mutation-status based on variables commonly included in epidemiologic datasets and evaluated the clinical utility of these approaches. Methods: Through analysis of the International Lung Cancer Consortium (ILCCO) epidemiologic datasets, we developed a regression model for EGFR-status; we then applied a clinical-restriction approach using the optimal cut-point, and a second epidemiologic, multiple imputation approach to ILCCO survival analyses that did and did not account for EGFR-status. Results: Of 35,356 ILCCO patients with NSCLC, EGFR-mutation-status was available in 4,231 patients. A model regressing known EGFR-mutation-status on clinical and demographic variables achieved a concordance index of 0.75 (95% CI, 0.74–0.77) in the training and 0.77 (95% CI, 0.74–0.79) in the testing dataset. At an optimal cut-point of probability-score = 0.335, sensitivity = 69% and specificity = 72.5% for determining EGFR-wildtype status. In both restriction-based and imputation-based regression analyses of the individual roles of BMI on overall survival of patients with NSCLC, similar results were observed between overall and EGFR-mutation-negative cohort analyses of patients of all ancestries. However, our approach identified some differences: EGFR-mutated Asian patients did not incur a survival benefit from being obese, as observed in EGFR-wildtype Asian patients. Conclusions: We introduce a pragmatic method to evaluate the potential impact of EGFR-status on epidemiological analyses of NSCLC. Impact: The proposed method is generalizable in the common occurrence in which EGFR-status data are missing.
- 1 March 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 31 (3) , 679-687
Open AccessAccounting for EGFR Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data
Background: Somatic EGFR mutations define a subset of non–small cell lung cancers (NSCLC) that have clinical impact on NSCLC risk and outcome. However, EGFR-mutation-status is often missing in epidemiologic datasets. We developed and tested pragmatic approaches to account for EGFR-mutation-status based on variables commonly included in epidemiologic datasets and evaluated the clinical utility of these approaches. Methods: Through analysis of the International Lung Cancer Consortium (ILCCO) epidemiologic datasets, we developed a regression model for EGFR-status; we then applied a clinical-restriction approach using the optimal cut-point, and a second epidemiologic, multiple imputation approach to ILCCO survival analyses that did and did not account for EGFR-status. Results: Of 35,356 ILCCO patients with NSCLC, EGFR-mutation-status was available in 4,231 patients. A model regressing known EGFR-mutation-status on clinical and demographic variables achieved a concordance index of 0.75 (95% CI, 0.74–0.77) in the training and 0.77 (95% CI, 0.74–0.79) in the testing dataset. At an optimal cut-point of probability-score = 0.335, sensitivity = 69% and specificity = 72.5% for determining EGFR-wildtype status. In both restriction-based and imputation-based regression analyses of the individual roles of BMI on overall survival of patients with NSCLC, similar results were observed between overall and EGFR-mutation-negative cohort analyses of patients of all ancestries. However, our approach identified some differences: EGFR-mutated Asian patients did not incur a survival benefit from being obese, as observed in EGFR-wildtype Asian patients. Conclusions: We introduce a pragmatic method to evaluate the potential impact of EGFR-status on epidemiological analyses of NSCLC. Impact: The proposed method is generalizable in the common occurrence in which EGFR-status data are missing.
- 1 August 2020
- Published by Elsevier in Lung Cancer
- Vol. 146, 350-354
ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases
- 1 August 2020
- Published by Elsevier in Lung Cancer
- Vol. 146, 350-354
ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases
- 20 May 2020
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (15_suppl) , 4544
Impact of body measurements (BM) on overall survival (OS) and quality of life (QoL) in real-world patients (pts) with metastatic esophageal cancer.
4544 Background: Body fat and muscle influence prognosis in many cancer types. However, this association is unclear for real-world MEC pts, who are often in worse performance status than their previous baseline. In addition, the relationship of BM at presentation and QoL is unknown. We used real-world MEC pts to assess the importance of BM in OS and QoL. Methods: BM were done at baseline computed tomography in MEC pts, treated from 2006-2014 at the Princess Margaret Cancer Centre. Two radiologists (correlation 0.9-1.0) assessed L3 level using SliceOMatic to determine Skeletal Muscle Index (SMI - muscle area at L3 normalized by height), Visceral Adiposity Tissue (VAT), and Subcutaneous Adiposity Tissue (SAT). We used previously published cut-offs for sarcopenia based on sex and BMI, and the highest tertile as the cut-off for adiposity. We used prospectively collected QoL surveys including EuroQol 5D-5L (EQ5D) and the Functional Assessment of Cancer Therapy – Esophageal (FACT-E). Results: Of 200 pts, 164 (82%) were male, 180 (92%) were non-Asian; mean age was 62 y; ECOG: 0-1 = 142 (71%), 2 = 58 (29%); 69% had adenocarcinoma; 5% were underweight, 44% normal weight, 30% overweight, and 21% obese. 40 (20%) pts completed QoL measures. We found that 104 (52%) were sarcopenic at baseline, 66 (33%) had high VAT, and 67 (34%) had high SAT. A multivariable Cox model showed that sarcopenia and VAT were independent prognostic variables for three-year OS: sarcopenia increased the risk of death by 50% (adjusted hazard ratio, aHR 1.50, p 0.02), whereas every 100-cm2 increase in VAT improved OS by 24% (aHR 0.76, p 0.03). Finally, sarcopenic pts had significantly worse physical well-being (p 0.01) on FACT-E after adjusting for sex and age. Numerically, the EQ5D also showed lower scores in sarcopenic pts but this was not statistically significant (p 0.18). Conclusions: In MEC pts, sarcopenia and low visceral adiposity result in worse OS; sarcopenia is also significantly associated with poor QoL. Future work will need to focus on potential rehabilitation strategies such as nutritional support and exercise training to offset the poor prognosis associated with sarcopenia and reduced adiposity. [Table: see text]
- 20 May 2020
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (15_suppl) , 4544
Impact of body measurements (BM) on overall survival (OS) and quality of life (QoL) in real-world patients (pts) with metastatic esophageal cancer.
4544 Background: Body fat and muscle influence prognosis in many cancer types. However, this association is unclear for real-world MEC pts, who are often in worse performance status than their previous baseline. In addition, the relationship of BM at presentation and QoL is unknown. We used real-world MEC pts to assess the importance of BM in OS and QoL. Methods: BM were done at baseline computed tomography in MEC pts, treated from 2006-2014 at the Princess Margaret Cancer Centre. Two radiologists (correlation 0.9-1.0) assessed L3 level using SliceOMatic to determine Skeletal Muscle Index (SMI - muscle area at L3 normalized by height), Visceral Adiposity Tissue (VAT), and Subcutaneous Adiposity Tissue (SAT). We used previously published cut-offs for sarcopenia based on sex and BMI, and the highest tertile as the cut-off for adiposity. We used prospectively collected QoL surveys including EuroQol 5D-5L (EQ5D) and the Functional Assessment of Cancer Therapy – Esophageal (FACT-E). Results: Of 200 pts, 164 (82%) were male, 180 (92%) were non-Asian; mean age was 62 y; ECOG: 0-1 = 142 (71%), 2 = 58 (29%); 69% had adenocarcinoma; 5% were underweight, 44% normal weight, 30% overweight, and 21% obese. 40 (20%) pts completed QoL measures. We found that 104 (52%) were sarcopenic at baseline, 66 (33%) had high VAT, and 67 (34%) had high SAT. A multivariable Cox model showed that sarcopenia and VAT were independent prognostic variables for three-year OS: sarcopenia increased the risk of death by 50% (adjusted hazard ratio, aHR 1.50, p 0.02), whereas every 100-cm2 increase in VAT improved OS by 24% (aHR 0.76, p 0.03). Finally, sarcopenic pts had significantly worse physical well-being (p 0.01) on FACT-E after adjusting for sex and age. Numerically, the EQ5D also showed lower scores in sarcopenic pts but this was not statistically significant (p 0.18). Conclusions: In MEC pts, sarcopenia and low visceral adiposity result in worse OS; sarcopenia is also significantly associated with poor QoL. Future work will need to focus on potential rehabilitation strategies such as nutritional support and exercise training to offset the poor prognosis associated with sarcopenia and reduced adiposity. [Table: see text]